📰 Area Under News
Page 7 - Area Under News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Area Under. Real-time updates on events, politics, business and more.
November 23, 2021
When it comes to getting business results from AI, the last mile is where it happens. But AI development projects invoke risk as well. Here's the pitfalls to address in the last mile of AI deployments.
August 27, 2021
Baoquocte.vn. Theo trang thống kê Worldometers, đến nay, toàn cầu ghi nhận gần 215,5 triệu ca nhiễm Covid-19, trong đó có xấp xỉ 4,49 triệu trường hợp tử vong và hơn 192,6 triệu bệnh nhân bình phục.
August 26, 2021
Investegate announcements from AstraZeneca PLC, ALXN1840 Wilson Phase III met primary endpoint
August 26, 2021
Positive high-level results from the FoCus Phase III trial in Wilson disease showed ALXN1840 met the primary endpoint with a statistically significant...
June 9, 2021
Lexaria Provides Progress Report on Six R&D Programs ACCESSWIRE 09 Jun 2021, 21:05 GMT+10 All studies are using DehydraTECH™ 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine These studies are part of Lexarias 2021 applied R&D program intended to enable opportunities for strategic partnerships KELOWNA, BC / ACCESSWIRE / June 9, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (the Company or Lexaria), a global...
May 27, 2021
27 May 2021 Plasma phospho-tau 181 and p-tau 217 can distinguish people with Alzheimer’s disease from controls most, but not all, of the time. To increase diagnostic accuracy, researchers are creating algorithms combining p-tau with other fluid biomarker and diagnostic data. In the May 24 Nature Medicine, researchers led by Oskar Hansson and Sebastian Palmqvist, both at Lund University, Sweden, reported just such an algorithm to predict AD. They report that among people with a subjective memo...
May 20, 2021
Lexaria Bioscience Corp.: Lexarias Newest DehydraTECH 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever Human clinical hypertension study HYPER-H21-1 also progressing KELOWNA, BC / ACCESSWIRE / May 20, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce successful test results of two new "DehydraTECH 2.0" cannabidiol ("CBD") fo...
May 20, 2021
Lexarias Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever ACCESSWIRE New formulation delivers up to 2,708% more CBD into bloodstream* Human clinical hypertension study HYPER-H21-1 also progressing KELOWNA, BC / ACCESSWIRE / May 20, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the Company or Lexaria), a global innovator in drug delivery platforms, is pleased to announce successful test results o...
May 6, 2021
Lexaria Bioscience Corp.: Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1 Up to 1,737% more CBD delivered into brain tissue* KELOWNA, BC / ACCESSWIRE / May 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce successful outcomes in its first sets of data from its 2021 applied research and development (R&D) study programs. Study HYPER-A21-1 included three ...